Cerebrospinal fluid IgM index correlates with cranial MRI lesion load in patients with multiple sclerosis

European Neurology

Volumn 58, Issue 2, 2007, Pages 90-95

  Jongen, Peter J H ^b,f   Lycklama A Nijeholt, Geert ^a   Lamers, Karel J B ^c   Doesburg, Wim H ^e   Barkhof, Frederik ^a   Lemmens, Wim A J G ^e   Klasen, Ina S ^d,e   Hommes, Otto R ^b  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b Multiple Sclerosis Centre Nijmegen   (Netherlands)

^c Institute of Neurology   (Netherlands)

^d RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^e RADBOUD UNIVERSITY NIJMEGEN   (Netherlands)

^f Multiple Sclerosis Centre Nijmegen   (Netherlands)

Author keywords

Cerebrospinal fluid; Cranial MRI; IgM; Intrathecal synthesis; Multiple sclerosis

Indexed keywords

COMPLEMENT COMPONENT C3; IMMUNOGLOBULIN M;

ADULT; ARTICLE; BRAIN ATROPHY; CEREBROSPINAL FLUID ANALYSIS; CLINICAL ARTICLE; CORRELATION ANALYSIS; DISEASE COURSE; FEMALE; HUMAN; IMMUNOGLOBULIN PRODUCTION; MALE; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN CEREBROSPINAL FLUID LEVEL;

ADULT; ATROPHY; BRAIN; COMPLEMENT SYSTEM PROTEINS; CROSS-SECTIONAL STUDIES; DISEASE PROGRESSION; FEMALE; HUMANS; IMMUNOGLOBULIN M; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; RECURRENCE; REMISSION, SPONTANEOUS;

EID: 34547728283     PISSN: 00143022     EISSN: None     Source Type: Journal    
DOI: 10.1159/000103643     Document Type: Article

References (26)

1. Thompson EJ: Cerebrospinal fluid. J Neurol Neurosurg Psychiatry 1995;59:349-357.
2. Perini P, Ranzato F, Calabrese M, Battistini L, Gallo P: Intrathecal IgM production at clinical onset correlates with a more severe disease course in multiple sclerosis. J Neurol Neurosurg Psychiatry 2006;77:953-955.
3. Prineas JW: The neuropathology of multiple sclerosis; in Koetsier JC (ed): Handbook of Clinical Neurology. Demyelinating Diseases. Amsterdam, Elsevier, 1985, vol 47, pp 337-395.
4. Lucchinetti CF, Brueck W, Parisi J, Scheithauer B, Rodriguez M, Lassmann H: Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann Neurol 2000;47:707-717.
5. Wekerle H, Lassmann H: Pathogenesis of demyelination and tissue damage; in Compston A (ed): McAlpine's Multiple Sclerosis. The Immunology of Inflammatory Demyelinating Disease. Philadelphia, Churchill Livingstone Elsevier, 2006, pp 536-540.
6. Poser CM, Paty DW, Scheinberg L, McDonald WI, Davis FA, Ebers GC, Johnson KP, Sibley WA, Silbergerg DH, Tourtelotte WW: New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983;13:227-231.
7. PRISMS Study Group: Randomised double-blind placebo-controlled study of interferon beta 1a in relapsing-remitting multiple sclerosis. Lancet 1998;352:1498-1504.
8. SPECTRIMS Study Group: Secondary progressing efficacy clinical trial of recombinant interferon-beta-1a in MS. Neurology 2001;56:1496-1504.
9. Jongen PJH, Lamers KJ, Doesburg WH, Lemmens WA, Hommes OR: Cerebrospinal fluid analysis differentiates between relapsing-remitting and secondary progressive multiple sclerosis. J Neurol Neurosurg Psychiatry 1997;63:446-451.
10. Jongen PJH, Floris S, Doesburg WH, Lemmens WA, Hommes OR, Lamers KJ: Composite cerebrospinal fluid score in relapsing-remitting and secondary progressive multiple sclerosis. Mult Scler 1998;4:108-110.
11. Jongen PJH, Boerbooms AMT, Lamers KJB, Raes BC, Vierwinden G: Diffuse CNS involvement in systemic lupus erythematosus: intrathecal synthesis of the 4th component of complement. Neurology 1990;40:1593-1596.
12. Lassmann H, Wekerle H: Pathogenic factors determining lesion topography; in Compston A (ed): McAlpine's Multiple Sclerosis. The Pathology of Multiple Sclerosis. Philadelphia, Churchill Livingstone Elsevier, 2006, pp 590-592.
13. Ciric B, Howe CL, Paz Soldan M, Warrington AE, Bieber AJ, Van Keulen V, Rodriguez M, Pease LR: Human monoclonal IgM antibody promotes CNS myelin repair independent of Fc function. Brain Pathol 2003;13:608-616.
14. Van Waesberghe JH, Kamphorst W, de Groot CJ, van Walderveen MA, Castelijns JA, Ravid R, Lycklama a Nijeholt GJ, van der Valk P, Polman CH, Thompson AJ, Barkhof F: Axonal loss in multiple sclerosis lesions: magnetic resonance imaging insights into substrates of disability. Ann Neurol 1999;46:747-754.
15. Sharief MK, Thompson EJ: Intrathecal immunoglobulin M synthesis in multiple sclerosis: relationship with clinical and cerebrospinal fluid parameters. Brain 1991;114:181-195.
16. Villar LM, Masjuan J, Gonzalez-Porque P, Plaza J, Sadaba MC, Roldan E, Bootello A, Alvarez-Cermeno JC: Intrathecal IgM in neurologic diseases: relationship with disability in MS. Neurology 2002;58:824-826.
17. Villar LM, Sadaba MC, Roldan E, Masjuan J, Gonzalez-Porque P, Villarrubbia N, Espino M, Plaza J, Garcia-Trujillo JA, Bootello A, Alvarez-Cermeno JC: Intrathecal synthesis of oligoclonal IgM against myelin lipids predicts aggressive disease course in MS. J Clin Invest 2005;115:187-194.
18. Villar LM, Masjuan J, Gonzalez-Porque P, Sadaba MC, Roldan E, Bootello A, Alvarez-Cermeno JC: Intrathecal IgM synthesis predicts the onset of new relapses and a worse disease course. Neurology 2002;59:555-559.
19. Barkhof F, McGowan JC, van Waesberghe JH, Grossman RI: Hypointense multiple sclerosis lesions on T1-weighted spin echo magnetic resonance images: their contribution in understanding multiple sclerosis evolution. J Neurol Neurosurg Psychiatry 1998;64(suppl 1):577-579.
20. Lassmann H, Kitz K, Wisniewski HM: In vivo effect of sera from animals with chronic relapsing experimental allergic encephalomyelitis on central and peripheral myelin. Acta Neuropathol 1981;55:297-306.
21. Schwarz M, Spector L, Gortier M, Weisshaus O, Glass-Marmor K, Karni A, Dotan N, Miller A: Serum anti-Glc(alpha1,4)Glc(alpha) antibodies as biomarker for relapsing-remitting multiple sclerosis. J Neurol Sci 2006;244:59-68.
22. Marconi S, Acler M, Lovato L, De Toni L, Tedeschi E, Anghileri E, Romito S, Cordioli C, Bonetti B: Anti-GD2-like IgM autoreactivity in multiple sclerosis. Mult Scler 2006;12:302-308.
23. Rosenbluth J, Schiff R, Liang WL, Dou W: Antibody-mediated CNS demyelination II: focal spinal cord lesions induced by implantation of an IgM antisulfatide-secreting hybridoma. J Neurocytol 2003;32:265-276.
24. Gay FW: Early cellular events in multiple sclerosis: intimations of an extrinsic myelinolytic antigen. Clin Neurol Neurosurg 2006;108:234-240.
25. Brink BP, Veerhuis R, Breij EC, van der Valk P, Dijkstra CD, Bo L: The pathology of multiple sclerosis is location-dependent: no significant complement activation is detected in purely cortical lesions. J Neuropathol Exp Neurol 2005;64:147-155.
26. Jongen PJH, Doesburg WH, Ibrahim-Stappers JL, Lemmens WA, Hommes OR, Lamers KJ: Cerebrospinal fluid C3 and C4 indexes in immunological disorders of the central nervous system. Acta Neurol Scand 2000;101:116-121.